About Max
This author has not written his bio yet.
But we are proud to say that Max contributed 797 entries already.
Entries by Max
Nuanced Benefits of Fasting-Mimicking Diets: High Protein vs. Low Protein
/in Clinical Trial/by MaxA recent study published in Clinical Nutrition sheds new light on the physiological impacts of Fasting-Mimicking Diets (FMDs), revealing that while both low-protein and high-protein versions offer significant health advantages, their specific benefits can differ notably. This randomized controlled trial explored the effects of a 7-day plant-based FMD with either a low protein/high fat (LP-FMD) […]
Newsletter 33/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! We have 3 clinical and 3 preclinical research today, but since the second half of August is always a bit “slow,” so I took the opportunity to create an article of my own that tries to summarize almost a […]
APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxA Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
Latest Posts
- Newsletter 32/2026 August 9, 2026
- Soon to Be Phase 1/2 Trial: Bria-PROS+ Receives FDA Clearance to Begin Clinical Study in Prostate Cancer August 6, 2026
- UPDATE: Seven Complete Responses in a 19-Patient Cohort of 67Cu-SAR-bisPSMA Trial for mCRPC August 6, 2026
- B7-H3: A Continuum-Wide, AR-Repressed Anchor for Combinatorial Prostate Cancer Therapy August 6, 2026
